We will be accepting DPhil student applications to start in October 2021 soon.
Professor of Experimental Radiotherapeutics
- Group Leader, Oxford Institute for Radiation Oncology
- Honorary Consultant in Clinical Oncology, Oxford University Hospitals NHS Trust
Our research focus is on understanding and exploiting the biological effects of external beam ionizing radiation and therapeutic radionuclides in solid tumours (breast, lung, pancreas, oesophageal and colorectal cancers among others).
Katherine undertook specialist training in Clinical Oncology at the Hammersmith Hospital and doctoral research at Edinburgh University. In 1995 she was appointed as Staff Radiation Oncologist at the Princess Margaret Hospital and Scientist at the Ontario Cancer Institute, Toronto. She returned to the UK in 2006 to join the Oxford Institute for Radiation Oncology and established the Experimental Radiotherapeutics Group.
Sarah Able, Laboratory Manager
Ole Tietz, Postdoctoral Researcher
Fernando Cortezon-Tamarit, Postdoctoral Researcher
Joao Lourenco, DPhil Student
Anis Theljani, Postdoctoral Researcher
Rachel Anderson, DPhil Student
Abirami Lakshminarayanan, Postdoctoral Researcher
Sreejesh Sreedharan, Postdoctoral Researcher
Stereotactic inverse dose planning following yttrium-90 selective internal radiotherapy in hepatocellular cancer
VALLIS K. et al, (2020), Advances in Radiation Oncology
Proton vs photon: A model-based approach to patient selection for reduction of cardiac toxicity in locally advanced lung cancer.
Teoh S. et al, (2020), Radiother Oncol, 152, 151 - 162
An 111In-labelled bis-ruthenium(ii) dipyridophenazine theranostic complex: Mismatch DNA binding and selective radiotoxicity towards MMR-deficient cancer cells
Gill MR. et al, (2020), Chemical Science, 11, 8936 - 8944
An 111In-labelled bis-ruthenium(II) dipyridophenazine theranostic complex: Mismatch DNA binding and selective radiotoxicity towards MMR-deficient cancer cells
VALLIS K., (2020), Chemical Science
The Impact of Radiobiologically-Informed Dose Prescription on the Clinical Benefit of Yttrium-90 SIRT in Colorectal Cancer Patients.
Abbott EM. et al, (2020), J Nucl Med